The Centers for Medicare & Medicaid Services proposed revisions to the National Coverage Determination for non‑invasive colorectal cancer (CRC) screening tests, lowering covered ages to 45–85 and raising performance thresholds for sensitivity and specificity. CMS would require FDA authorization, CLIA processing, and ongoing post‑approval studies to retain coverage. The proposal cites USPSTF guidance and tightens prior thresholds, potentially reshaping the market for blood‑ and stool‑based CRC tests. Exact Sciences, Guardant, Geneoscopy and emerging blood‑based developers such as Freenome were named in the policy discussion. CMS opened a public comment period, signaling commercial and regulatory implications for test makers and payors.